Changchun Bcht Biotechnology Co. Ltd. has obtained marketing approval for its live attenuated zoster vaccine in China, making it the first approved shingles vaccine developed by a Chinese company. An injectable of 0.5 ml per dose, it is designed for adults ages 40 and older and will go up against GSK plc’s Shingrix vaccine.
Using a near-atomic resolution cryo-electron microscope and imaging techniques that prevent loss of information, scientists at the La Jolla Institute for Immunology (LJI) and Regeneron Pharmaceuticals Inc. have obtained the complete 3D structure of the glycoprotein of the Ebola virus and that of the drug that neutralizes it, Inmazeb, the first FDA-approved treatment for this deadly virus. “The challenge was embracing the inherent asymmetry, the heterogeneity that is really there in biology, understanding it and collecting enough data to get all the images without needing to force any symmetry averaging,” senior author Erica Ollmann Saphire told BioWorld.
Tonix Pharmaceuticals Holding Corp. has announced it plans to develop the TNX-3900 series of oral antivirals as monotherapy or in combination with other antivirals, following an agreement whereby it has acquired all of the assets of Healion Bio Inc., including its entire portfolio of next-generation antiviral technology assets.
Researchers from Central Drug Research Institute (CDRI) and the Academy of Scientific & Innovative Research (AcSIR) have synthesized and evaluated a series of novel antileishmanial agents. Synthesis and optimization of a series of halogen-rich salicylanilides led to the discovery of compounds [I] and [II], which demonstrated the best antileishmanial activity, with IC50 values of 2.89 μM and 2.09 μM, respectively against Leishmania donovani amastigote.
Changchun Bcht Biotechnology Co. Ltd. has obtained marketing approval for its live attenuated zoster vaccine in China, making it the first approved shingles vaccine developed by a Chinese company. An injectable of 0.5 ml per dose, it is designed for adults ages 40 and older and will go up against GSK plc’s Shingrix vaccine.
State University of New Jersey and Tufts University have patented compounds with ability to modulate Mycobacterium tuberculosis (Mtb) response to high environmental chloride and acidic pH for Mtb growth inhibition reported to be useful for the treatment of tuberculosis.
Greenlight Biosciences Holdings PBC has received regulatory approval from the Rwanda Food and Drugs Authority (Rwanda FDA) to start a first-in-human phase I/II trial of its mRNA vaccine candidate against COVID-19, GLB-COV2-043, as a booster for previously vaccinated individuals.
RSS
